Contact
searchSearch
HMP Global

February 2014 - FRMC

Cost Savings with Bortezomib, Cyclophosphamide, and Dexamethasone
02/19/2014
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with untreated multiple myeloma had a cost savings of approximately $29,000 per treatment course if they received bortezomib, cyclophosphamide, and dexamethasone (BCD) compared with a group taking bortezomib,...
New Orleans—Patients with...
02/19/2014
First Report Managed Care
Omacetaxine for CML
02/19/2014
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24 months of follow-up, heavily pretreated patients with chronic phase or accelerated phase chronic myeloid leukemia (CML) had clinically meaningful and durable responses to omacetaxine, according to a subset...
New Orleans—After at least 24...
02/19/2014
First Report Managed Care
Dabigatran to Treat Patients with Acute Venous Thromboembolism
02/19/2014
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified subgroup analysis of 2 randomized, phase 3 trials that included patients with acute venous thromboembolism (VTE) found that there was no difference in recurrent VTE or VTE-related mortality if they received...
New Orleans—A prespecified...
02/19/2014
First Report Managed Care
Treatment with Rituximab in Clinics and Offices versus Hospitals
02/19/2014
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective...
02/19/2014
First Report Managed Care
Phase 2 Trial of Obinutuzumab for Advanced DLBCL
02/19/2014
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) tolerated a regimen of obinutuzumab and chemotherapy, according to a phase 2, open label, multicenter, single arm trial. The authors mentioned preliminary results...
New Orleans—Patients newly...
02/19/2014
First Report Managed Care
Allogeneic HSCT and Cognitive Impairment
02/19/2014
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic hematopoietic stem cell transplantation had cognitive impairment on executive function, processing speed, and verbal fluency.
Patients undergoing allogeneic...
02/19/2014
First Report Managed Care
Economic Benefit Suggested with Abatacept for RA
02/19/2014
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as first- or second-line treatment for patients with moderate-to-severe rheumatoid arthritis (RA) may have an economic benefit over other biologic disease-modifying antirheumatic drugs (DMARDs) agents, as...
  San Diego—Use of abatacept as...
02/19/2014
First Report Managed Care
Efficacy of Golimumab for Refractory RA Maintained Over 5 Years
02/19/2014
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes show that golimumab maintains its efficacy for patients with active rheumatoid arthritis (RA) who failed prior biologic therapy with anti-tumor necrosis factor (TNF) therapy.
San Diego—Long-term outcomes...
02/19/2014
First Report Managed Care
Tofacitinib Monotherapy Offers Significant Benefits for Active RA
02/19/2014
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with rheumatoid arthritis (RA), tofacitinib monotherapy significantly inhibits progression of structural damage, improves signs and symptoms of disease, and improves function over 2 years compared to patients treated...
San Diego—In patients with...
02/19/2014
First Report Managed Care

Department

Conference Insider
Ustekinumab for Patients with Active PsA Long-Term
02/19/2014
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and safety of ustekinumab as treatment for active psoriatic arthritis (PsA) is maintained at 100 weeks follow-up, according to long-term data presented at the ACR/ARHP meeting.
San Diego—The efficacy and...
02/19/2014
First Report Managed Care
FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

What's Trending?

Newsfeed
At-Home PrEP Test Kits Discounted for World AIDS Day
12/04/2018
Through December 7, 2018, a telemedicine company is discounting its HIV prevention service line in recognition of the 30th anniversary of World AIDS Day.
Through December 7, 2018, a telemedicine company is discounting its HIV prevention service line in recognition of the 30th anniversary of World AIDS Day.
Through December 7, 2018, a...
12/04/2018
First Report Managed Care
News
A bitter health care pill
08/11/2010
08/11/2010
First Report Managed Care
Department
Drug Prices Play Central Role in Cancer Treatment Value Decisions
02/15/2017
Increasing exposure of patients to actual drug prices, through reduced insurance coverage, has made cost a necessary factor in cancer treatment value discussions, argued Peter P Bach, MD, MAPP, director of the Center for Health Policy and...
Increasing exposure of patients to actual drug prices, through reduced insurance coverage, has made cost a necessary factor in cancer treatment value discussions, argued Peter P Bach, MD, MAPP, director of the Center for Health Policy and...
Increasing exposure of patients...
02/15/2017
First Report Managed Care
News
Optional Medicaid benefits face state cuts
12/06/2011
12/06/2011
First Report Managed Care
News
Silver Plan Cost-Sharing Options for 2015 Health Insurance
02/20/2015
A recent report reviewed the main cost-sharing options in various health plans available through the federal marketplace based on data collected by Healthcare.gov.
A recent report reviewed the main cost-sharing options in various health plans available through the federal marketplace based on data collected by Healthcare.gov.
A recent report reviewed the...
02/20/2015
First Report Managed Care

Video Insights

Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

February 2014 Volume 11 Issue 2

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use